media – Page 31 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Tilpotide wins head to head over semaglutide, with a GLP-1 market worth billions, ushering in the era of “duopoly”

The competition in the GLP-1 track is becoming increasingly fierce, and the game between giants to grab the market is becoming more and more obvious. On May 11th, Eli Lilly and Company released research data on SURMUNT-5, which exploded like a bombshell in the global weight loss drug market. Its new GLP-1/GIP dual receptor agonist, Tilpotide, outperformed Novo Nordisk’s semaglutide in key indicators such as weight loss of 20.2% vs 13.7% and waist circumference reduction of 18.4cm vs 13.0cm. According to the data disclosed by Eli Lilly, in the primary endpoint of the study, telapride achieved a relative weight loss of 1.47 times compared to semaglutide. According to research data based on treatment plan estimation goals, at week 72, the average weight loss rate achieved by telmisartan was 20.2%, while that of semaglutide was 13.7%. The average weight loss of the Tilpotide group was 22.8kg, and the average weight loss ...
- Source: drugdu
- 124
- May 15, 2025
The continuous development of innovative drugs by Yuanda Pharmaceutical has attracted capital attention, with a stock price increase of over 38% in 5 trading days

On the evening of May 12th, Yuanda Pharmaceutical once again disclosed the new progress of a globally innovative radionuclide coupled drug TLX591 CDx under research. The Phase III clinical trial of this drug in China has been completed with all patients enrolled for administration, and it is planned to submit a new drug application for market launch in China this year. This is the third major innovative research and development progress announced by Yuanda Pharmaceutical since May 6th. From May 7th to May 12th, the stock price of Yuanda Pharmaceutical rose strongly and reached a historical high of HKD 8.95 per share on May 12th. On May 13th, the stock price slightly fell, and as of the close, the stock price was HKD 8.29 per share, with a cumulative increase of 38.4% from May 7th to May 13th. This year, with the recovery of pharmaceutical stocks, the position of innovative ...
- Source: drugdu
- 77
- May 15, 2025
FDA and RFK Jr. Aim to Remove Ingestible Fluoride Products Used to Protect Kids’ Teeth

WASHINGTON (AP) — U.S. health regulators announced an effort Tuesday to phase out ingestible fluoride supplements sometimes used to strengthen children’s teeth, opening a new front in Health Secretary Robert F. Kennedy Jr.’s effort against a mainstay of dental care. The Food and Drug Administration said it will conduct a scientific review of the children’s products by late October with the aim of removing them from the market. Formally withdrawing medical products requires a lengthy rulemaking process that can take years. Instead, the FDA will ask manufacturers to voluntarily pull their products, according to an administration official. Fluoride tablets and lozenges are sometimes recommended for children and teens at increased risk of tooth decay or cavities because of low fluoride in their local drinking water. Companies also sell drops for babies. FDA Commissioner Marty Makary said the products pose a risk when swallowed because they may interfere with healthy gut ...
- Source: drugdu
- 100
- May 15, 2025
Unique Challenges in Repurposing Drugs for Addiction Treatment

In the fast-paced and capital-intensive world of biopharma, early-stage companies face a complex web of challenges—from securing funding and protecting IP to navigating regulatory and commercial pathways. Armando Castro, Partner in the Emerging Companies & Venture Capital practice at Lowenstein Sandler, brings deep legal and strategic expertise to the table, guiding innovative startups through these pivotal moments. In an interview with Pharmaceutical Executive, Castro shares his insights on the current funding environment, trends in biotech dealmaking, and how early-stage life sciences companies can position themselves for long-term success. Pharmaceutical Executive: Are there any unique regulatory or legal risks that investors should be aware of when evaluating companies repurposing GLP-1 drugs for addiction therapy? Armando Castro: There are unique challenges in this space. One of them—perhaps unexpectedly—is the patent issue I mentioned earlier. You might think, “I’m taking an existing substance and entering a new market,” only to discover that repurposing ...
- Source: drugdu
- 74
- May 15, 2025
Protamine Human Insulin Injection Obtains Overseas Drug Registration Certificate

May 13, Tonghua Dongbao, the company announced that it had recently received a drug registration certificate for protamine human insulin injection approved and issued by the National Health Regulatory Agency of Nicaragua (ANRS). Protamine human insulin injection is suitable for type 1 or type 2 diabetes. The main ingredient is human insulin, which is produced through genetic recombination technology. It can promote the uptake and utilization of glucose by tissues such as the liver, muscle and fat, inhibit the decomposition of liver glycogen and gluconeogenesis, and thus lower blood sugar levels. Protamine can slowly release insulin and prolong its duration of action. https://finance.eastmoney.com/a/202505133403178852.html
- Source: drugdu
- 72
- May 15, 2025
Sinopharm Modern Pharmaceuticals’ subsidiary’s Amikacin Sulfate Injection passed the consistency evaluation

On May 13, Sinopharm Modern issued an announcement that recently, its wholly-owned subsidiary Sinopharm Rongsheng Pharmaceutical Co., Ltd. received the “Notice of Approval of Drug Supplementary Application” approved and issued by the National Drug Administration, approving Amikacin Sulfate Injection to pass the generic drug quality and efficacy consistency evaluation. The announcement mentioned that the sales of amikacin sulfate injection in public medical institutions across the country will be 233 million yuan in 2024. So far, Sinopharm Rongsheng has invested approximately 4.59 million yuan (unaudited) in research and development for the consistency evaluation of the drug. In the first quarter of 2025, Sinopharm Modern achieved revenue of 2.607 billion yuan and net profit attributable to shareholders of the parent company of 361 million yuan. https://finance.eastmoney.com/a/202505133403270474.html
- Source: drugdu
- 68
- May 15, 2025
US drug prices will drop by 30%-80% immediately

On the evening of May 11th local time, US President Trump stated on social media that he would sign an executive order at 9 am the next day (9 pm Beijing time on the 12th) with the goal of immediately reducing US prescription drug and medicine prices by 30% to 80%.Image source: Truth Social Trump believes that drug prices in the United States are much higher than in other countries, and the price of the same drug in the United States may be several times that of other countries. This policy mainly includes the implementation of the “most favored nation policy”, allowing the United States to enjoy the same price treatment as the countries with the lowest drug prices in the world, and the US government will renegotiate prices with pharmaceutical companies. If this policy can be implemented, it will greatly reduce the medical burden on the American people, especially ...
- Source: drugdu
- 58
- May 15, 2025
AS treatment! TNF-α declines, IL-17 and JAK open new battlefields!

Some diseases can make people look up at the sky forever, while some diseases can also make people look at the ground forever, and this is ankylosing spondylitis. Regarding the pain points of ankylosing spondylitis (AS), in addition to the spine that is as stiff as if it were poured with cement when you wake up in the morning, this chronic inflammatory disease is like a silent “bone erosion war”, spreading from the sacroiliac joints to the spine, and even affecting peripheral joints such as the hip and knee, eventually leaving the patient in the dilemma of “the body gradually becoming petrified.” This “immortal tumor” is even more despairing to the patient’s biological quality than most terminal illnesses. 4 million people cannot stand up straight all year round Strictly speaking, ankylosing spondylitis (AS) is a refractory chronic inflammatory autoimmune disease that mainly affects the sacroiliac joints, spine, paraspinal soft tissues ...
- Source: drugdu
- 70
- May 15, 2025
ROMMEDICA

Organiser：ROMEXPO S.A., Romania Time：October 16 – 18, 2025 address：65-67 Marasti Blvd., 011465 București, Romania Exhibition hall：Romexpo Product range: Electronic medical instruments Organ support, stimulation, and replacement devices Anesthesia, resuscitation, and critical care equipment Diagnostic instruments and equipment Endoscopic diagnostic and therapeutic devices Surgical supplies and equipment Emergency rescue equipment Sterilization, disinfection, and water treatment equipment Hospital/clinic furniture and equipment Disposable items/hospital consumables Rehabilitation equipment and supplies Orthopedic products and equipment Pharmaceutical products Ophthalmic/optical elements and equipment Medical light sources Microsurgery Laboratory equipment Medical services Medical consultations, etc. About ROMMEDICA： The Romania Medical Equipment Exhibition (ROMMEDICA) stands as a traditional event in the Romanian medical market, offering an opportunity to promote the latest advancements in the medical field. The exhibition organizes seminars, conferences, and roundtable discussions to foster ideas that drive development and enhance the quality of Romania’s healthcare system.
- Source: drugdu
- 116
- May 15, 2025
Fudan University establishes the “Baili Tianheng Distinguished Professor” program

On the occasion of the 120th anniversary of the founding of Fudan University, Zhu Yi, a 1984 graduate of the Department of Biology and founder, chairman, and chief scientific officer of Sichuan Baili Tianheng Pharmaceutical Co., Ltd., as well as the founder and chairman of Syst Immune, Inc. (Seattle Immunology), donated RMB 30 million in cash to establish the “Fudan University Baili Tianheng Distinguished Professor” project, supporting Fudan University in nurturing a group of outstanding technology leaders in areas such as “Innovative Drug Target Discovery” and “Brain and Brain like Intelligence Research”. Zhu Yi once said in an interview that whether it is basic research or product innovation, real talents are always scarce. The insight and scientific beliefs possessed by innovative talents are important factors in promoting the development of enterprises. The establishment of the “Fudan University Baili Tianheng Distinguished Professor” project is also due to Zhu Yi’s emphasis on ...
- Source: drugdu
- 119
- May 14, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.